Pneumococcal Conjugate vaccine for adults launched in India by Pfizer | Medical Learner

Pfizer has officially launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India.

This single-dose vaccine is approved for adults aged 18 years and above and provides protection against 20 different strains of Streptococcus pneumoniae the bacteria responsible for serious infections like pneumonia, meningitis, and bloodstream infections.

With broader coverage than any previous conjugate vaccine available in India, PCV20 aims to reduce the burden of both invasive and non-invasive pneumococcal diseases.

The single-dose schedule is designed for convenience and greater vaccine compliance, especially for high-risk adults, such as those with chronic diseases or weakened immune systems.

Source : https://www.expresshealthcare.in

The launch of PCV20 is a major step forward in India’s adult immunization strategy, offering strong protection, long-lasting immunity, and simplified dosing making it easier to protect millions of adults from life threatening infections.

Have thoughts or questions about PCV‑20?

Drop them in the comments below let’s discuss.